BMS inhibits CHI3L1 (chitinase 3-like-1) stimulation of ACE2 (angiotensin-converting enzyme 2) and SPP (viral spike protein priming proteases) and can be potentially used for COVID-19 therapy [44]. The gene discussed is ACE2; the disease is COVID-19.